Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.

NCT Number	NCT05194397
Lead Sponsor	Children's Hospital of Philadelphia Collaborators: National Institutes of Health (NIH), City of Hope Medical Center, St. Jude Children's Research Hospital, National Cancer Institute (NCI), University of Pennsylvania
Conditions	Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Enrollment	80 participants
Start Date	2023-02-23
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-04